Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $17.07, but opened at $17.75. Ascentage Pharma Group International shares last traded at $17.65, with a volume of 1,045 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research report on Wednesday. They issued a “buy” rating and a $45.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The company has a 50-day simple moving average of $22.53 and a 200-day simple moving average of $24.99.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. As a group, equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG increased its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at $383,000. XY Capital Ltd increased its holdings in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. Finally, ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.